The Asia Pacific vaccine adjuvants market was valued at US$ 518.07 million in 2022 and is expected to reach US$ 1,546.43 million by 2030; it is estimated to register a CAGR of 14.6% from 2022 to 2030.
The vaccine adjuvants market presents significant opportunities due to the growing demand for enhanced vaccine efficacy and the expansion of vaccine applications beyond traditional infectious diseases. As new pathogens emerge and existing ones evolve, there is an increasing need for adjuvants that can boost immune responses and provide broader protection. Advancements in biotechnology and immunology are driving innovation in adjuvant formulations, offering novel solutions for both preventive and therapeutic vaccines. Additionally, the rise in global vaccination programs and increased funding for vaccine research are fueling market growth. Companies focusing on developing adjuvants with improved safety profiles and higher effectiveness are well-positioned to capitalize on this expanding market. Strategic partnerships and collaborations with research institutions and biotechnology firms can further enhance opportunities in this dynamic field, making it a promising area for investment and development.
The Asia Pacific vaccine adjuvant market has been segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Strategic initiatives, such as collaborations between Chinese companies to produce adjuvant vaccines, drive the market. For instance, in April 2020, Dynavax Technologies Corporation announced a collaboration with Chinese biopharmaceutical company Sinovac to develop CpG 1018 adjuvant. CpG 1018 is the adjuvant used in HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], an adult hepatitis B vaccine approved by the US Food and Drug Administration (FDA) to increase vaccine immune response. Therefore, strategic developments such as collaboration and partnerships by the Chinese manufacturers for procuring adjuvanted vaccines is a standalone factor responsible for positive market growth.
The Asia Pacific vaccine adjuvants market is categorized into adjuvant class, type, and country.
Based on adjuvant class, the Asia Pacific vaccine adjuvants market is segmented into mineral salt adjuvant, emulsion adjuvant, liposome adjuvant, and others. The mineral salt adjuvant segment held the largest share of the Asia Pacific vaccine adjuvants market share in 2022.
By type, the Asia Pacific vaccine adjuvants market is bifurcated into human vaccine adjuvant and veterinary vaccine adjuvant. The human vaccine adjuvant segment held a larger share of Asia Pacific vaccine adjuvants market in 2022.
By country, the Asia Pacific vaccine adjuvants market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific vaccine adjuvants market share in 2022.
Croda International Plc; CSL Ltd; GSK Plc; Hawaii Biotech Inc; InvivoGen SAS; Novavax Inc; Phibro Animal Health Corp; and SPI Pharma Inc are some of the leading companies operating in the Asia Pacific vaccine adjuvants market.